Frequent Transmission of Streptococcus pneumoniae Serotype 35B and 35D, Clonal Complex 558 Lineage, across Continents and the Formation of Multiple Clades in Japan-Reference-Cited by-同舟云学术

Frequent Transmission of Streptococcus pneumoniae Serotype 35B and 35D, Clonal Complex 558 Lineage, across Continents and the Formation of Multiple Clades in Japan

Published:2023-02-16 Issue:2 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Shinohara Koh¹^ORCID,Fujisawa Takao²,Chang Bin³,Ito Yutaka⁴^ORCID,Suga Shigeru²,Matsumura Yasufumi¹^ORCID,Yamamoto Masaki¹,Nagao Miki¹,Ohnishi Makoto³,Sugai Motoyuki⁵^ORCID,Nakano Satoshi¹⁵^ORCID

Affiliation:

1. Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

2. National Hospital Organization Mie National Hospital, Tsu, Japan

3. Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan

4. Nagoya City University, Graduate School of Medical Science, Nagoya, Japan

5. Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan

Abstract

Streptococcus pneumoniae is a common bacterial pathogen that causes infections in children worldwide, even after administration of the pneumococcal conjugate vaccine. S. pneumoniae serotype 35B, especially the clonal complex 558 (CC558) lineage, has emerged globally following implementation of the 13-valent pneumococcal conjugate vaccine. Serotype 35B strains are also associated with multidrug resistance to both β-lactams and non-β-lactam drugs.

Funder

Japan Agency for Medical Research and Development

MEXT | Japan Society for the Promotion of Science

Pfizer

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01083-22

Reference53 articles.

1. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15